Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Jun 7

PMID 31168359

Citations 12

Authors

Feng Su

George N Ioannou

Affiliations

Soon will be listed here.

Citing Articles

Hepatocyte transformation is induced by laminin γ2 monomer.

Funahashi N, Okada H, Kaneko R, Nio K, Yamashita T, Koshikawa N Cancer Sci. 2024; 115(9):2972-2984.

PMID: 38951133 PMC: 11462950. DOI: 10.1111/cas.16265.

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of....

Gedallovich S, Kwo P Clin Mol Hepatol. 2024; 30(4):677-681.

PMID: 38858182 PMC: 11540361. DOI: 10.3350/cmh.2024.0418.

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.

Ezzat W, Amr K, Tawfeek S, Elbatae H, Bayomi E, Heiba A BMC Infect Dis. 2024; 24(1):67.

PMID: 38195397 PMC: 10775543. DOI: 10.1186/s12879-023-08016-2.

Review of heart transplantation from hepatitis C-positive donors.

Patel P, Patel N, Ahmed F, Gluck J World J Transplant. 2022; 12(12):394-404.

PMID: 36570408 PMC: 9782687. DOI: 10.5500/wjt.v12.i12.394.

Viral Hepatitis Among African Immigrants with Hepatocellular Carcinoma in Minnesota: High Prevalence Yet Low Awareness.

Udompap P, Moscoso C, Anugwom C, Kc M, Lim N, Lake J J Immigr Minor Health. 2022; 25(2):357-364.

PMID: 36109400 DOI: 10.1007/s10903-022-01400-1.

References

. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016; 65(4):734-740. DOI: 10.1016/j.jhep.2016.05.045. View

Li D, Ren Y, Fierer D, Rutledge S, Shaikh O, Lo Re 3rd V . The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2017; 67(6):2244-2253. DOI: 10.1002/hep.29707. View

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G . Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int. 2017; 37(8):1122-1127. DOI: 10.1111/liv.13456. View

Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H . Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2017; 62(10):2932-2942. DOI: 10.1007/s10620-017-4739-z. View

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo M, Madonia S . Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017; 46(7):688-695. DOI: 10.1111/apt.14256. View

Saraiya N, Yopp A, Rich N, Odewole M, Parikh N, Singal A . Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018; 48(2):127-137. PMC: 6019180. DOI: 10.1111/apt.14823. View

Beste L, Leipertz S, Green P, Dominitz J, Ross D, Ioannou G . Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015; 149(6):1471-1482.e5. DOI: 10.1053/j.gastro.2015.07.056. View

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D . Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology. 2018; 155(5):1436-1450.e6. DOI: 10.1053/j.gastro.2018.07.015. View

10.

Huang A, Mehta N, Dodge J, Yao F, Terrault N . Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018; 68(2):449-461. PMC: 6097892. DOI: 10.1002/hep.29855. View

11.

Backus L, Belperio P, Shahoumian T, Mole L . Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology. 2017; 69(2):487-497. DOI: 10.1002/hep.29408. View

12.

Singal A, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo Y . Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2009; 8(2):192-9. DOI: 10.1016/j.cgh.2009.10.026. View

13.

Kanwal F, Kramer J, Asch S, Chayanupatkul M, Cao Y, El-Serag H . Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153(4):996-1005.e1. DOI: 10.1053/j.gastro.2017.06.012. View

14.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A . Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018; 155(2):411-421.e4. DOI: 10.1053/j.gastro.2018.04.008. View

15.

Morgan R, Baack B, Smith B, Yartel A, Pitasi M, Falck-Ytter Y . Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5 Pt 1):329-37. DOI: 10.7326/0003-4819-158-5-201303050-00005. View

16.

Ioannou G, Green P, Berry K . HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017; . PMC: 5837901. DOI: 10.1016/j.jhep.2017.08.030. View

17.

Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T . Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017; 67(5):933-939. DOI: 10.1016/j.jhep.2017.05.028. View

18.

Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay J, Vanwolleghem T . The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. J Viral Hepat. 2017; 24(11):976-981. DOI: 10.1111/jvh.12726. View

19.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P . Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016; 65(4):727-733. DOI: 10.1016/j.jhep.2016.06.015. View

20.

Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y . Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 2018; 13(4):e0194704. PMC: 5901785. DOI: 10.1371/journal.pone.0194704. View